Status:
COMPLETED
Implementation of a Personalized Medicine (Pharmacogenomics) Service in a Community Pharmacy
Lead Sponsor:
University of North Carolina, Chapel Hill
Collaborating Sponsors:
Kerr Drug
Laboratory Corporation of America
Conditions:
Stroke
Transient Ischemic Attack
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to determine the feasibility of pharmacogenomics testing in a community pharmacy using clopidogrel as an example. The investigators hypothesize that this testing is feasib...
Detailed Description
To determine if the study is feasible, we will examine the change in patient perception of pharmacogenomics testing (before and after the study), the percentage of patients interested in this service,...
Eligibility Criteria
Inclusion
- Prescribed clopidogrel (Plavix) by their prescriber
- Aged 18 or older
- Currently on clopidogrel therapy for one of the following indicated uses: post-ACS, Recent PCI with stenting, History of TIA or stroke
Exclusion
- Are unable to complete study materials (surveys) with or without assistance, including non-English speaking patients
- Are taking clopidogrel for a reason other than stated in inclusion criteria
- Are pregnant or nursing
- Have an allergy to aspirin
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT01495845
Start Date
December 1 2011
End Date
June 1 2012
Last Update
June 8 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kerr Drug
Chapel Hill, North Carolina, United States, 27517